Understanding Immune Cell Changes in Sepsis
This observational study is looking at how certain immune cells, called myeloid-derived suppressor cells (MDSCs), change in people with sepsis (a life-threatening response to infection) or trauma. Researchers want to understand why these cells might become "dysfunctional" and contribute to ongoing inflammation or a weakened immune system after sepsis. They will measure the number of neutrophils and early MDSCs to see how these cells are affected. You might be able to join if you are 18 to 100 years old and meet the criteria for sepsis. The study aims to understand the underlying reasons for poor recovery and complications after sepsis by studying these immune cells over time.
- Study design
- This is an observational study planning to enroll 450 participants. It is not a treatment study, but rather aims to understand how the body responds to sepsis.
- What's involved
- You would provide blood samples. The study will measure certain immune cells at 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your immune cell levels will be measured at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Lyle Moldawer, PhD · PRINCIPAL_INVESTIGATOR · University of Florida
- Philip Efron, MD · PRINCIPAL_INVESTIGATOR · University of Florida
- Tyler Loftus, MD · PRINCIPAL_INVESTIGATOR · University of Florida
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The total number of neutrophils and early myeloid derived suppressor cells will be measured and will be used to determine the magnitude of myelopoiesis dysfunction.6 months
The total number of neutrophils and early Myeloid derived suppressor cells will be measured at sepsis onset and during hospitalization and at 3 and 6 months.